All In Biotech

Drug Trial Radar · NCT07607561

Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration

A Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter, Phase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
SCAI TherapeuticsIndustry
Sponsor type
Industry
First posted
May 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial to Evaluate the Safety and Efficacy of SCAI-005 Ophthalmic solution in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to investigate the efficacy, safety and tolerability of SCAI-005 Ophthalmic solution by dose in patients with neovascular Age-related Macular Degeneration (nAMD).

Conditions

  • wetAMD
  • Age Related Macular Degeneration

Interventions

  • SCAI-005 0.04% 2drops TIDDrug

    Axitinib 0.084mg/day

  • SCAI-005 0.08% 2drops TIDDrug

    Axinitib 0.168mg/day

  • Placebo 2drops TIDDrug

    vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Central Subfield ThicknessTime frame: 12weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.